Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery
ConditionSugammadex
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, Davis
About this trial
This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age greater than 18 years
scheduled for an elective laparoscopic gastric bypass procedure
Disqualifiers
age less than 18 years
pregnancy
prisoners
significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
Trial population
Patients scheduled for surgical procedures in the UC Davis Medical Center main ORs will be screened for potential enrollment.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Quantitative Neuromuscular Function Monitoring
DeviceQuantitative electromyographic (EMG) monitoring
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Oxygen desaturation
Incidence and magnitude of significant oxygen desaturation
Time frame
24 hoursSecondary outcomes
1
The rate of compliance with muscle relaxant monitoring and reversal protocols
Rate of compliance (%)
Time frame
24 hours2
Total intraoperative rocuronium use
Total dose/kg/hr (mg/kg/hr)
Time frame
24 hours3
Total sugammadex dose
Total dose (mg/kg)
Time frame
24 hours4
Post-operative supplemental oxygen requirement
Oxygen requirement (FiO2%/hr)
Time frame
24 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov